Back
Daktronics 10K Form
Buy
59
DAKT
Daktronics
Last Price:
$16.96
Seasonality Move:
-1.69%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-02-28 | 10Q | DAKT/Daktronics Quarterly |
2023-12-05 | 10Q | DAKT/Daktronics Quarterly |
2023-09-08 | 10Q | DAKT/Daktronics Quarterly |
2023-03-13 | 10Q | DAKT/Daktronics Quarterly |
2022-12-13 | 10Q | DAKT/Daktronics Quarterly |
2022-09-02 | 10Q | DAKT/Daktronics Quarterly |
Receive DAKT News And Ratings
See the #1 stock for the next 7 days that we like better than DAKT
DAKT Financial Statistics
Sales & Book Value
Annual Sales: | $818.1M |
---|---|
Cash Flow: | $38M |
Price / Cash Flow: | 13.02 |
Annual Sales: | $5.56 |
Price / Book: | 3.05 |
Profitability
EPS (TTM): | 0.25000 |
---|---|
Net Income (TTM): | $29.7M |
Gross Margin: | $222.4M |
Return on Equity: | 12.41% |
Return on Assets: | 5.62% |
Daktronics Earnings Forecast
Key Daktronics Financial Ratios
-
The Gross Profit Margin over the past 32 years for DAKT is 27.19%.
-
The Selling, General & Administrative Expenses for DAKT have been equal to 12.17% of Gross Profit Margin.
-
The Research & Development expenses have been 4.37% of Revenue.
-
The Interest Expense is 2.75% of Operating Income.
-
The Net Earning history of DAKT is 4.23% of Total Revenues.
-
Per Share Earnings over the last 32 years have been positive in 19 years.
Daktronics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Electronic Equipment, Instruments & Components |
Sector: | Information Technology |
Current Symbol: | DAKT |
CUSIP: | 234264 |
Website: | daktronics.com |
Debt
Debt-to-Equity Ratio: | 0.25 |
---|---|
Current Ratio: | 2.35 |
Quick Ratio: | 1.62 |
Price-to-Earnings
Trailing P/E Ratio: | 22.91 |
---|---|
Forward P/E Ratio: | 15.69 |
DAKT Technical Analysis vs Fundamental Analysis
Buy
59
Daktronics (DAKT)
is a Buy
Is Daktronics a Buy or a Sell?
-
Daktronics stock is rated a BuyThe current Daktronics [DAKT] share price is $16.95. The Score for DAKT is 59, which is 18% above its historic median score of 50, and infers lower risk than normal.